{"doi":"10.1111/ajco.12850","title":"Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T‐CL","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>To better understand the T‐cell immunodeficiency status in patients with peripheral T‐cell lymphomas (PTCLs) and NK/T‐cell lymphomas (NK/T‐CLs), the T‐cell inhibitory receptors expression pattern was investigated.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The expression levels of programmed death 1 (<jats:italic>PD‐1</jats:italic>), cytotoxic T lymphocyte‐associated antigen 4 (<jats:italic>CTLA‐4</jats:italic>), B/T lymphocyte attenuator (<jats:italic>BTLA</jats:italic>), lymphocyte‐activation gene 3 (<jats:italic>LAG‐3</jats:italic>), T‐cell immunoglobulin‐3 (<jats:italic>TIM‐3</jats:italic>), T‐cell immunoglobulin and ITIM domain (<jats:italic>TIGIT</jats:italic>) genes were detected in peripheral blood mononuclear cells (PBMCs) from patients and healthy volunteers by quantitative real‐time‐PCR, the correlation between different gene expression levels was analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Significantly higher expression of <jats:italic>PD‐1, CTLA‐4, BTLA, LAG‐3, TIM‐3</jats:italic> and <jats:italic>TIGIT</jats:italic> can be observed as a common characteristic in patients with PTCL or NK/T‐CL. However, the coexpression pattern seemed different between subtypes. Their overexpression is also related to disease progression stage.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>We first characterized the expression pattern of six T‐cell inhibitory receptor genes in PTCL and NK/T‐CL, which might work as immune biomarkers for evaluation the immunosuppression status and help to establish the precision targets of immunotherapy.</jats:p></jats:sec>","journal":"Asia-Pacific Journal of Clinical Oncology","year":2018,"id":597488,"datarank":0.40620753016533157,"base_score":2.70805020110221,"endowment":2.70805020110221,"self_citation_contribution":0.40620753016533157,"citation_network_contribution":0.0,"self_endowment_contribution":0.40620753016533157,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1530733,"name":"Xuewen Lv","orcid":null,"position":1,"is_corresponding":false},{"id":1530734,"name":"Sichu Liu","orcid":null,"position":2,"is_corresponding":false},{"id":1530735,"name":"Zifan He","orcid":null,"position":3,"is_corresponding":false},{"id":19029,"name":"Shaohua Chen","orcid":"0000-0001-8306-2626","position":4,"is_corresponding":false},{"id":404181,"name":"Liang Wang","orcid":"0000-0002-5247-6727","position":5,"is_corresponding":false},{"id":637900,"name":"Wenyu Li","orcid":"0000-0003-0218-589X","position":6,"is_corresponding":false},{"id":335210,"name":"Yangqiu Li","orcid":"0000-0002-0974-4036","position":7,"is_corresponding":false},{"id":1108314,"name":"Ziwei Liao","orcid":"0000-0003-0882-7056","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T‐CL","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>To better understand the T‐cell immunodeficiency status in patients with peripheral T‐cell lymphomas (PTCLs) and NK/T‐cell lymphomas (NK/T‐CLs), the T‐cell inhibitory receptors expression pattern was investigated.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The expression levels of programmed death 1 (<jats:italic>PD‐1</jats:italic>), cytotoxic T lymphocyte‐associated antigen 4 (<jats:italic>CTLA‐4</jats:italic>), B/T lymphocyte attenuator (<jats:italic>BTLA</jats:italic>), lymphocyte‐activation gene 3 (<jats:italic>LAG‐3</jats:italic>), T‐cell immunoglobulin‐3 (<jats:italic>TIM‐3</jats:italic>), T‐cell immunoglobulin and ITIM domain (<jats:italic>TIGIT</jats:italic>) genes were detected in peripheral blood mononuclear cells (PBMCs) from patients and healthy volunteers by quantitative real‐time‐PCR, the correlation between different gene expression levels was analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Significantly higher expression of <jats:italic>PD‐1, CTLA‐4, BTLA, LAG‐3, TIM‐3</jats:italic> and <jats:italic>TIGIT</jats:italic> can be observed as a common characteristic in patients with PTCL or NK/T‐CL. However, the coexpression pattern seemed different between subtypes. Their overexpression is also related to disease progression stage.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>We first characterized the expression pattern of six T‐cell inhibitory receptor genes in PTCL and NK/T‐CL, which might work as immune biomarkers for evaluation the immunosuppression status and help to establish the precision targets of immunotherapy.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":2.70805020110221,"endowment":2.70805020110221,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"29368793","pmcid":null,"openalex_id":"https://openalex.org/W2794254531","authors":[],"funders":[{"funder_name":"National Natural Science Foundation of China","grant_id":"91642111","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"81570143","title":null},{"funder_name":"Guangdong Science and Technology Department","grant_id":"2015A050502029","title":null},{"funder_name":"Guangdong Science and Technology Department","grant_id":"2016A020215123","title":null}],"total_grants":4,"fwci":1.0586,"citation_percentile":0.7456709,"influential_citations":0,"citation_trend":[{"year":2018,"count":2},{"year":2019,"count":2},{"year":2020,"count":1},{"year":2021,"count":2},{"year":2022,"count":3},{"year":2023,"count":1},{"year":2024,"count":2},{"year":2025,"count":1}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fajco.12850","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.12850","host_type":"publisher"},{"url":"https://doi.org/10.1111/ajco.12850","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/29368793","host_type":"repository"}],"fields_of_study":["Lymphoma Diagnosis and Treatment","Chronic Lymphocytic Leukemia Research","Cancer Immunotherapy and Biomarkers","Antigens, CD","Biomarkers, Tumor","CTLA-4 Antigen","Female","Hepatitis A Virus Cellular Receptor 2","Humans","Lymphoma, Extranodal NK-T-Cell","Lymphoma, T-Cell, Peripheral","Programmed Cell Death 1 Receptor","Receptors, Immunologic","Lymphocyte Activation Gene 3 Protein"],"mesh_terms":["Hepatitis A Virus Cellular Receptor 2","Lymphocyte Activation Gene 3 Protein","Female","Humans","Receptors, Immunologic","Biomarkers, Tumor","Antigens, CD","Lymphoma, T-Cell, Peripheral","Lymphoma, Extranodal NK-T-Cell","CTLA-4 Antigen","Programmed Cell Death 1 Receptor"],"keywords":["TIGIT","BTLA","Cytotoxic T cell","Immunology","T cell","Immune system","Biology","Antibody","Peripheral blood mononuclear cell","Interleukin 21","Medicine","CTLA-4","PD-1","TIM-3","Ptcl","Lag-3","Nk/t-cl"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T13:24:50.253763Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}